IAG (Image Analysis Group) Partner with IMV to Advance Clinical Development of DPX-Survivac in the Treatment of Solid Tumors
London, UK, May 8th 2019 – IAG, Image Analysis Group, a strategic imaging partner for bio-pharma companies, announced they have entered into an collaboration with IMV’s to validate how advanced imaging techniques can help assess the tumor microenvironment in a subset of patients in IMV’s ongoing phase 2 basket trial, which is evaluating DPX-Survivac in combination with pembrolizumab in multiple solid tumor indications.
Under the terms of the collaboration, IMV and IAG will use multi-parametric MRI (mpMRI) and IAG’s artificial intelligence imaging methodologies in an exploratory arm in IMV’s phase 2 multicenter basket study. This trial is assessing the combination of DPX-Survivac, pembrolizumab, and low dose cyclophosphamide in patients across five indications: ovarian cancer, hepatocellular carcinoma (HCCC), non-small-cell lung carcinoma (NSCLC), microsatellite instability-high (MSI-H) solid tumors, and bladder cancer.
In the exploratory arm utilizing the mpMRI techniques, researchers will calculate advanced imaging biomarkers in support of RECIST1.1 and iRECIST assessment. mpMRI is designed to more clearly demonstrate the potential efficacy of immunotherapies and provide reliable assessments of tumor changes. The financial terms of the deal are not being disclosed.
“Artificial intelligence-driven methodologies applied to advanced imaging have the potential to transform the pharmaceutical industry and drug development. This partnership will allow us comprehensively explore DPX-Survivac’s mechanism of action and build solid scientific data, while potentially reducing the development costs, timelines, and uncertainties,” said Dr. Diana Roettger, Head of Therapeutic Innovation, IAG.
“The global pharmaceutical industry and major investors recognize the critical importance of deploying technological innovation in efficient drug development. We are excited to partner with IMV and support the success of their programs,” added Dr. Olga Kubassova, CEO of IAG.
Organizers of the 2019 Annual Society of Clinical Oncology (ASCO) Annual Meeting published an abstract highlighting the methodology on May 15, entitled “Early response assessment through multiparametric MRI based endpoints in a phase II multicenter study evaluating the efficacy of DPX-Survivac, intermittent low dose cyclophosphamide (CPA) and pembrolizumab combination study in subjects with solid tumors.”
About IAG
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. ia-grp.com